Trial site
CHU de Toulouse - Hopital Larrey
Toulouse, Haute-Garonne 31059, FranceNot linked to an institution yet
- 11running trials
- 4closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 22 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Active, not recruiting5 trials
- Recruiting5 trials
- Completed4 trials
- Not yet recruiting1 trial
- Lead sponsor
- Hoffmann-La Roche3 trials
- Eli Lilly and Company2 trials
- Calluna Pharma AS1 trial
- Chiesi Farmaceutici S.p.A.1 trial
- Dizal Pharmaceuticals1 trial
- and 7 more
Running trials
Not yet recruiting
Prevalence of Nocturnal Hypoventilation in Obese Subjects Fiited With Continuous Positive Airway Pressure for Obstructive Sleep Apnea / Hypopnea Syndrome
NCT07152990· University Hospital, Toulouse· Source
Contact: Sandrine PONTIER
Active, not recruiting
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
NCT06736990· Phase 2· Calluna Pharma AS· Source
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Julien Mazieres (principal investigator)
Recruiting
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
NCT06487078· Pfizer· Source
Recruiting
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
NCT06423573· Chiesi Farmaceutici S.p.A.· Source
Contact: Juliette Mazereeuw Hautier
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891· EMD Serono Research & Development Institute, Inc.· Source
Contact: Julien Mazieres (principal investigator)
Active, not recruiting
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022· Phase 1/2· Dizal Pharmaceuticals· Source
Active, not recruiting
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
NCT03570021· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Active, not recruiting
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03774732· Phase 3· UNICANCER· Source
Active, not recruiting
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error